Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Ghez

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
European Journal of Haematology|September 1, 2022
Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B-cell lymphomaAdrien Daniel, David Ghez, Camille Ravaiau, et al.
Blood Advances|December 6, 2024
Venetoclax-proteasome inhibitor-dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasmSabine Khalife-Hachem, Arnaud Pages, Elie Akoury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2019
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple MyelomaTimothy A Brighton, Amit Khot, Simon J Harrison, et al.
Blood|February 14, 2018
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinibDavid Ghez, Anne Calleja, Caroline Protin, et al.
Leukemia & Lymphoma|November 29, 2017
Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemiaMathilde Ruggiu, Florence Oberkampf, David Ghez, et al.
European Journal of Cancer (Oxford, England : 1990)|December 5, 2025
Waldenström's macroglobulinemia: The LYSA pragmatic guidelinesDamien Roos-Weil, Cécile Tomowiak, Stéphanie Poulain, et al.
Bulletin Du Cancer|January 1, 2018
[Hodgkin lymphoma: Current and future therapeutic strategies]Anthony Turpin, Jean-Marie Michot, Emmanuelle Kempf, et al.
Plos One|May 30, 2008
Case-control cohort study of patients' perceptions of disability in mastocytosisOlivier Hermine, Olivier Lortholary, Phillip S Leventhal, et al.
Hemasphere|June 24, 2022
Therapy-related Myeloid Neoplasms in Patients With Chronic Lymphocytic Leukemia Who Received FCR/FC as Frontline TherapyKamel Laribi, Alix Baugier de Materre, David Ghez, et al.
American Journal of Hematology|April 5, 2019
Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO groupAnne Quinquenel, Sophie Godet, Caroline Dartigeas, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
European Journal of Haematology|September 1, 2022
Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B-cell lymphomaAdrien Daniel, David Ghez, Camille Ravaiau, et al.
Blood Advances|December 6, 2024
Venetoclax-proteasome inhibitor-dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasmSabine Khalife-Hachem, Arnaud Pages, Elie Akoury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2019
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple MyelomaTimothy A Brighton, Amit Khot, Simon J Harrison, et al.
Blood|February 14, 2018
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinibDavid Ghez, Anne Calleja, Caroline Protin, et al.
Leukemia & Lymphoma|November 29, 2017
Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemiaMathilde Ruggiu, Florence Oberkampf, David Ghez, et al.
European Journal of Cancer (Oxford, England : 1990)|December 5, 2025
Waldenström's macroglobulinemia: The LYSA pragmatic guidelinesDamien Roos-Weil, Cécile Tomowiak, Stéphanie Poulain, et al.
Bulletin Du Cancer|January 1, 2018
[Hodgkin lymphoma: Current and future therapeutic strategies]Anthony Turpin, Jean-Marie Michot, Emmanuelle Kempf, et al.
Plos One|May 30, 2008
Case-control cohort study of patients' perceptions of disability in mastocytosisOlivier Hermine, Olivier Lortholary, Phillip S Leventhal, et al.
Hemasphere|June 24, 2022
Therapy-related Myeloid Neoplasms in Patients With Chronic Lymphocytic Leukemia Who Received FCR/FC as Frontline TherapyKamel Laribi, Alix Baugier de Materre, David Ghez, et al.
American Journal of Hematology|April 5, 2019
Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO groupAnne Quinquenel, Sophie Godet, Caroline Dartigeas, et al.
Pageof 8